Lynx Reports Lower Q3 Revenues Amid Flat Expenses; Stock Rises and Falls | GenomeWeb

NEW YORK, Nov. 15 (GenomeWeb News) - Lynx Therapeutics posted today a sharp drop in third-quarter revenues, as operating costs stayed unchanged.


Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.